126 related articles for article (PubMed ID: 12187626)
1. [Down-regulation of a gene-expression by an antisense BNA oligonucleotide].
Imanishi T; Obika S
Nihon Yakurigaku Zasshi; 2002 Aug; 120(2):85-90. PubMed ID: 12187626
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes.
Hanecak R; Brown-Driver V; Fox MC; Azad RF; Furusako S; Nozaki C; Ford C; Sasmor H; Anderson KP
J Virol; 1996 Aug; 70(8):5203-12. PubMed ID: 8764029
[TBL] [Abstract][Full Text] [Related]
3. Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs).
Nulf CJ; Corey D
Nucleic Acids Res; 2004; 32(13):3792-8. PubMed ID: 15263060
[TBL] [Abstract][Full Text] [Related]
4. Target gene knockdown by 2',4'-BNA/LNA antisense oligonucleotides in zebrafish.
Itoh M; Nakaura M; Imanishi T; Obika S
Nucleic Acid Ther; 2014 Jun; 24(3):186-91. PubMed ID: 24460393
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of bcl-xL expression by antisense oligonucleotides containing various bridged nucleic acids (BNAs).
Roongjang S; Takahashi K; Obika S; Imanishi T
Nucleic Acids Symp Ser (Oxf); 2007; (51):113-4. PubMed ID: 18029612
[TBL] [Abstract][Full Text] [Related]
6. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation.
Tallet-Lopez B; Aldaz-Carroll L; Chabas S; Dausse E; Staedel C; Toulmé JJ
Nucleic Acids Res; 2003 Jan; 31(2):734-42. PubMed ID: 12527783
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression.
Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M
Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C IRES: translating translation into a therapeutic target.
Jubin R
Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352
[TBL] [Abstract][Full Text] [Related]
10. RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.
Mutso M; Nikonov A; Pihlak A; Žusinaite E; Viru L; Selyutina A; Reintamm T; Kelve M; Saarma M; Karelson M; Merits A
PLoS One; 2015; 10(6):e0128686. PubMed ID: 26039055
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue.
Rahman SM; Seki S; Obika S; Yoshikawa H; Miyashita K; Imanishi T
J Am Chem Soc; 2008 Apr; 130(14):4886-96. PubMed ID: 18341342
[TBL] [Abstract][Full Text] [Related]
12. Optimization of 2',4'-BNA/LNA-Based Oligonucleotides for Splicing Modulation In Vitro.
Shimo T; Obika S
Methods Mol Biol; 2018; 1828():395-411. PubMed ID: 30171556
[TBL] [Abstract][Full Text] [Related]
13. Antisense activity of 2',4'-BNA targeted to bcl-xL gene in HepG2 cell.
Roongjang S; Takahashi K; Park M; Obika S; Imanishi T
Nucleic Acids Symp Ser (Oxf); 2006; (50):289-90. PubMed ID: 17150931
[TBL] [Abstract][Full Text] [Related]
14. Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors.
Yamamoto T; Yasuhara H; Wada F; Harada-Shiba M; Imanishi T; Obika S
J Nucleic Acids; 2012; 2012():707323. PubMed ID: 23056920
[TBL] [Abstract][Full Text] [Related]
15. Antigene-block strategy: effective regulation of gene expression by 2',4'-BNA-modified TFOs with an additional stem-loop structure.
Tsuda N; Matsumoto A; Ito A; Uneda T; Tanabe A; Obika S; Imanishi T
Nucleic Acids Symp Ser (Oxf); 2005; (49):335-6. PubMed ID: 17150770
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ICAM-1 gene expression by antisense 2',4'-BNA oligonucleotides.
Obika S; Hemamayi R; Masuda T; Sugimoto T; Nakagawa S; Mayumi T; Imanishi T
Nucleic Acids Res Suppl; 2001; (1):145-6. PubMed ID: 12836306
[TBL] [Abstract][Full Text] [Related]
17. Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin-2.
Horie S; Suzuki Y; Yamamoto T; Obika S; Mohri K; Kiyota C; Ren Q; Warashina S; Wada Y; Watanabe Y; Mukai H; Sato Y
Cancer Sci; 2023 Sep; 114(9):3740-3749. PubMed ID: 37430466
[TBL] [Abstract][Full Text] [Related]
18. Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro.
Alotte C; Martin A; Caldarelli SA; Di Giorgio A; Condom R; Zoulim F; Durantel D; Hantz O
Antiviral Res; 2008 Dec; 80(3):280-7. PubMed ID: 18625270
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and properties of 3'-amino-2',4'-BNA, a bridged nucleic acid with a N3'-->P5' phosphoramidate linkage.
Obika S; Rahman SM; Song B; Onoda M; Koizumi M; Morita K; Imanishi T
Bioorg Med Chem; 2008 Oct; 16(20):9230-7. PubMed ID: 18812260
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and properties of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides.
Morita K; Takagi M; Hasegawa C; Kaneko M; Tsutsumi S; Sone J; Ishikawa T; Imanishi T; Koizumi M
Bioorg Med Chem; 2003 May; 11(10):2211-26. PubMed ID: 12713831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
